Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Eoganachton Feb 08, 2024 1:58pm
293 Views
Post# 35870521

RE:Excellent News

RE:Excellent NewsYes, this is excellent news! 

Dr. Jewett understands Theralase's treatment inside and out. In 2018 he was the one who presented the Phase II clinical protocol and study design to the other members of Theralase's Medical and Scientific Advisory Board for review and approval.

In 2018 he was the chair of Theralase's MSAB and presented the upcoming phase 2 trial on a Business Television interview:

Dr. Jewett Interview on BTD

At the 2019 AGM he presented an overview of the phase 2 trial. In the first half of the video Dr. Kulkarni presented the results of the Phase 1 study. Starting at 10 mins. 58 secs. Dr. Jewett provides a detailed description of the Phase 2.

Overview of Phase II Clinical Study

A transcript of his presentation is available here:

Transcript of Dr. Jewett's Presentation at the June 2019 AGM

<< Previous
Bullboard Posts
Next >>